Lexicon Pharmaceuticals Inc
LXRX
Company Profile
Business description
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
Contact
2445 Technology Forest Boulevard
11th Floor
The WoodlandsTX77381
USAT: +1 281 863-3000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
81
Stocks News & Analysis
stocks
SpaceX: What investors need to know about its enormous upcoming IPO
Morningstar launches research coverage of SpaceX.
stocks
Fair value lifts for toll road operator as Aussie fuel supply steadies
An Australian fuel shortage is becoming increasingly unlikely, a relief for ASX toll road operator.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,966.00 | 17.10 | 0.19% |
| CAC 40 | 8,207.15 | 60.56 | 0.74% |
| DAX 40 | 25,191.73 | 188.69 | 0.75% |
| Dow JONES (US) | 51,078.88 | 46.42 | 0.09% |
| FTSE 100 | 10,371.84 | 32.89 | 0.32% |
| HKSE | 26,038.32 | 640.14 | 2.52% |
| NASDAQ | 27,086.81 | 114.19 | 0.42% |
| Nikkei 225 | 66,734.24 | 200.09 | -0.30% |
| NZX 50 Index | 13,170.71 | 73.84 | -0.56% |
| S&P 500 | 7,599.96 | 19.90 | 0.26% |
| S&P/ASX 200 | 8,724.40 | 17.70 | 0.20% |
| SSE Composite Index | 4,075.10 | 17.36 | 0.43% |